MAPT and Alzheimer disease: Preclinical neuroprotective evidence and plausible mechanisms of SFN in AD have been widely investigated in animal and cell models, suggesting that sulforaphane has a multiple neuroprotective effect on AD pathophysiology regarding amyloid-β, tau, inflammation, oxidative stress, and memory impairment [52, 53].